Autolus Therapeutics Files 8-K

Ticker: AUTL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1730463

Autolus Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.000042
Sentimentneutral

Sentiment: neutral

Topics: reporting, regulatory

Related Tickers: AUTL

TL;DR

Autolus filed a routine 8-K, no major news.

AI Summary

Autolus Therapeutics plc filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Autolus Therapeutics plc, without disclosing any new material events or financial performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no new material information, indicating low immediate risk.

Key Players & Entities

  • Autolus Therapeutics plc (company) — Registrant
  • January 13, 2025 (date) — Date of Report

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact name of the registrant?

The exact name of the registrant is Autolus Therapeutics plc.

On what date was this report filed?

The report was filed on January 13, 2025.

What is the principal executive office address of Autolus Therapeutics plc?

The principal executive office address is The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom.

Does this filing disclose any specific financial results or material events?

No, this filing primarily serves as a notification of Regulation FD Disclosure and the submission of Financial Statements and Exhibits, without detailing specific financial results or new material events.

Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 06:47:22

Key Financial Figures

  • $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Autolus Therapeutics plc (the "Company") will make a corporate update presentation at the J.P. Morgan Health Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the conference, and posted to the Company's website as an updated corporate presentation. The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Exhibits

Item 9.01 Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Corporate Presentation dated J anuary 13 , 202 5 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: January 13, 2025 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.